ANCA-Associated Vasculitis: Core Curriculum 2020

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2020-01, Vol.75 (1), p.124-137
Hauptverfasser: Geetha, Duvuru, Jefferson, J. Ashley
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 137
container_issue 1
container_start_page 124
container_title American journal of kidney diseases
container_volume 75
creator Geetha, Duvuru
Jefferson, J. Ashley
description Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with >75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.
doi_str_mv 10.1053/j.ajkd.2019.04.031
format Article
fullrecord <record><control><sourceid>elsevier_webof</sourceid><recordid>TN_cdi_webofscience_primary_000503198700017</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638619308261</els_id><sourcerecordid>S0272638619308261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</originalsourceid><addsrcrecordid>eNqNkMtKxDAUhoMozjj6Ai6ke2lNcpo0FTeleINBN-o2pEkKqTPTIWkV394M1VmKZJEL_3dOvoPQOcEZwQyuukx17yajmJQZzjMM5ADNCaOQcgHiEM0xLWjKQfAZOgmhwxiXwPkxmgEBJoCQOcLVU12lVQi9dmqwJnlTQY8rN7hwndS9t0k9eu_i07hOKKb4FB21ahXs2c--QK93ty_1Q7p8vn-sq2WqGWFDSoyOLZSOH-VtbiAHJYxocohXiy3kSpQ0LlY2wItGlEzZVjUlgcZYY3JYIDrV1b4PwdtWbr1bK_8lCZY7fdnJnb7c6Uucy6gfoYsJ2o7N2po98usbA5dT4NM2fRu0sxtt97E4IBbLlKKIJ1LEtPh_unaDGly_qftxM0T0ZkJtnNGHs17-4MZ5qwdpeveXyDd0aood</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Geetha, Duvuru ; Jefferson, J. Ashley</creator><creatorcontrib>Geetha, Duvuru ; Jefferson, J. Ashley</creatorcontrib><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with &gt;75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2019.04.031</identifier><identifier>PMID: 31358311</identifier><language>eng</language><publisher>PHILADELPHIA: Elsevier Inc</publisher><subject>anti-neutrophil cytoplasmic antibody (ANCA) ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy ; Antibodies, Antineutrophil Cytoplasmic - immunology ; autoantibody ; Churg-Strauss Syndrome - genetics ; Churg-Strauss Syndrome - immunology ; Churg-Strauss Syndrome - pathology ; Churg-Strauss Syndrome - therapy ; complement ; cyclophosphamide ; Cyclophosphamide - therapeutic use ; Disease Progression ; glomerulonephritis ; Glomerulonephritis - genetics ; Glomerulonephritis - immunology ; Glomerulonephritis - pathology ; Glomerulonephritis - therapy ; Glucocorticoids - therapeutic use ; granulomatosis with polyangiitis (GPA) ; Granulomatosis with Polyangiitis - genetics ; Granulomatosis with Polyangiitis - immunology ; Granulomatosis with Polyangiitis - pathology ; Granulomatosis with Polyangiitis - therapy ; Humans ; immunosuppression ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation ; Life Sciences &amp; Biomedicine ; microscopic polyangiitis (MPA) ; Microscopic Polyangiitis - genetics ; Microscopic Polyangiitis - immunology ; Microscopic Polyangiitis - pathology ; Microscopic Polyangiitis - therapy ; Mycophenolic Acid - therapeutic use ; Myeloblastin - immunology ; Peroxidase - immunology ; Remission Induction ; Renal Dialysis ; review ; rituximab ; Rituximab - therapeutic use ; Science &amp; Technology ; Urology &amp; Nephrology ; Vasculitis</subject><ispartof>American journal of kidney diseases, 2020-01, Vol.75 (1), p.124-137</ispartof><rights>2019 National Kidney Foundation, Inc.</rights><rights>Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>251</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000503198700017</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2019.04.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31358311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Jefferson, J. Ashley</creatorcontrib><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><title>American journal of kidney diseases</title><addtitle>AM J KIDNEY DIS</addtitle><addtitle>Am J Kidney Dis</addtitle><description>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with &gt;75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</description><subject>anti-neutrophil cytoplasmic antibody (ANCA)</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy</subject><subject>Antibodies, Antineutrophil Cytoplasmic - immunology</subject><subject>autoantibody</subject><subject>Churg-Strauss Syndrome - genetics</subject><subject>Churg-Strauss Syndrome - immunology</subject><subject>Churg-Strauss Syndrome - pathology</subject><subject>Churg-Strauss Syndrome - therapy</subject><subject>complement</subject><subject>cyclophosphamide</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease Progression</subject><subject>glomerulonephritis</subject><subject>Glomerulonephritis - genetics</subject><subject>Glomerulonephritis - immunology</subject><subject>Glomerulonephritis - pathology</subject><subject>Glomerulonephritis - therapy</subject><subject>Glucocorticoids - therapeutic use</subject><subject>granulomatosis with polyangiitis (GPA)</subject><subject>Granulomatosis with Polyangiitis - genetics</subject><subject>Granulomatosis with Polyangiitis - immunology</subject><subject>Granulomatosis with Polyangiitis - pathology</subject><subject>Granulomatosis with Polyangiitis - therapy</subject><subject>Humans</subject><subject>immunosuppression</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>microscopic polyangiitis (MPA)</subject><subject>Microscopic Polyangiitis - genetics</subject><subject>Microscopic Polyangiitis - immunology</subject><subject>Microscopic Polyangiitis - pathology</subject><subject>Microscopic Polyangiitis - therapy</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Myeloblastin - immunology</subject><subject>Peroxidase - immunology</subject><subject>Remission Induction</subject><subject>Renal Dialysis</subject><subject>review</subject><subject>rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>Science &amp; Technology</subject><subject>Urology &amp; Nephrology</subject><subject>Vasculitis</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkMtKxDAUhoMozjj6Ai6ke2lNcpo0FTeleINBN-o2pEkKqTPTIWkV394M1VmKZJEL_3dOvoPQOcEZwQyuukx17yajmJQZzjMM5ADNCaOQcgHiEM0xLWjKQfAZOgmhwxiXwPkxmgEBJoCQOcLVU12lVQi9dmqwJnlTQY8rN7hwndS9t0k9eu_i07hOKKb4FB21ahXs2c--QK93ty_1Q7p8vn-sq2WqGWFDSoyOLZSOH-VtbiAHJYxocohXiy3kSpQ0LlY2wItGlEzZVjUlgcZYY3JYIDrV1b4PwdtWbr1bK_8lCZY7fdnJnb7c6Uucy6gfoYsJ2o7N2po98usbA5dT4NM2fRu0sxtt97E4IBbLlKKIJ1LEtPh_unaDGly_qftxM0T0ZkJtnNGHs17-4MZ5qwdpeveXyDd0aood</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Geetha, Duvuru</creator><creator>Jefferson, J. Ashley</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202001</creationdate><title>ANCA-Associated Vasculitis: Core Curriculum 2020</title><author>Geetha, Duvuru ; Jefferson, J. Ashley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-1dc358ac1056f4d343a8d8b4356fe0e34a89292959b367b895aefab913bdedd43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>anti-neutrophil cytoplasmic antibody (ANCA)</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy</topic><topic>Antibodies, Antineutrophil Cytoplasmic - immunology</topic><topic>autoantibody</topic><topic>Churg-Strauss Syndrome - genetics</topic><topic>Churg-Strauss Syndrome - immunology</topic><topic>Churg-Strauss Syndrome - pathology</topic><topic>Churg-Strauss Syndrome - therapy</topic><topic>complement</topic><topic>cyclophosphamide</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease Progression</topic><topic>glomerulonephritis</topic><topic>Glomerulonephritis - genetics</topic><topic>Glomerulonephritis - immunology</topic><topic>Glomerulonephritis - pathology</topic><topic>Glomerulonephritis - therapy</topic><topic>Glucocorticoids - therapeutic use</topic><topic>granulomatosis with polyangiitis (GPA)</topic><topic>Granulomatosis with Polyangiitis - genetics</topic><topic>Granulomatosis with Polyangiitis - immunology</topic><topic>Granulomatosis with Polyangiitis - pathology</topic><topic>Granulomatosis with Polyangiitis - therapy</topic><topic>Humans</topic><topic>immunosuppression</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>microscopic polyangiitis (MPA)</topic><topic>Microscopic Polyangiitis - genetics</topic><topic>Microscopic Polyangiitis - immunology</topic><topic>Microscopic Polyangiitis - pathology</topic><topic>Microscopic Polyangiitis - therapy</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Myeloblastin - immunology</topic><topic>Peroxidase - immunology</topic><topic>Remission Induction</topic><topic>Renal Dialysis</topic><topic>review</topic><topic>rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>Science &amp; Technology</topic><topic>Urology &amp; Nephrology</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geetha, Duvuru</creatorcontrib><creatorcontrib>Jefferson, J. Ashley</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geetha, Duvuru</au><au>Jefferson, J. Ashley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANCA-Associated Vasculitis: Core Curriculum 2020</atitle><jtitle>American journal of kidney diseases</jtitle><stitle>AM J KIDNEY DIS</stitle><addtitle>Am J Kidney Dis</addtitle><date>2020-01</date><risdate>2020</risdate><volume>75</volume><issue>1</issue><spage>124</spage><epage>137</epage><pages>124-137</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3–ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics. AAV has a predilection for the kidney, with &gt;75% of patients having renal involvement characterized by rapidly progressive glomerulonephritis. The cause and pathogenesis of AAV are multifactorial and influenced by genetics, environmental factors, and responses of the innate and adaptive immune system. Randomized controlled trials in the past 2 decades have refined the therapy of AAV and transformed AAV from a fatal disease to a chronic illness with relapsing course and associated morbidity. This article in AJKD’s Core Curriculum in Nephrology series provides a detailed review of the epidemiology, pathogenesis, diagnosis, and advances in the management of AAV.</abstract><cop>PHILADELPHIA</cop><pub>Elsevier Inc</pub><pmid>31358311</pmid><doi>10.1053/j.ajkd.2019.04.031</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2020-01, Vol.75 (1), p.124-137
issn 0272-6386
1523-6838
language eng
recordid cdi_webofscience_primary_000503198700017
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects anti-neutrophil cytoplasmic antibody (ANCA)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - genetics
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - pathology
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - therapy
Antibodies, Antineutrophil Cytoplasmic - immunology
autoantibody
Churg-Strauss Syndrome - genetics
Churg-Strauss Syndrome - immunology
Churg-Strauss Syndrome - pathology
Churg-Strauss Syndrome - therapy
complement
cyclophosphamide
Cyclophosphamide - therapeutic use
Disease Progression
glomerulonephritis
Glomerulonephritis - genetics
Glomerulonephritis - immunology
Glomerulonephritis - pathology
Glomerulonephritis - therapy
Glucocorticoids - therapeutic use
granulomatosis with polyangiitis (GPA)
Granulomatosis with Polyangiitis - genetics
Granulomatosis with Polyangiitis - immunology
Granulomatosis with Polyangiitis - pathology
Granulomatosis with Polyangiitis - therapy
Humans
immunosuppression
Immunosuppressive Agents - therapeutic use
Kidney Transplantation
Life Sciences & Biomedicine
microscopic polyangiitis (MPA)
Microscopic Polyangiitis - genetics
Microscopic Polyangiitis - immunology
Microscopic Polyangiitis - pathology
Microscopic Polyangiitis - therapy
Mycophenolic Acid - therapeutic use
Myeloblastin - immunology
Peroxidase - immunology
Remission Induction
Renal Dialysis
review
rituximab
Rituximab - therapeutic use
Science & Technology
Urology & Nephrology
Vasculitis
title ANCA-Associated Vasculitis: Core Curriculum 2020
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T02%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANCA-Associated%20Vasculitis:%20Core%20Curriculum%202020&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Geetha,%20Duvuru&rft.date=2020-01&rft.volume=75&rft.issue=1&rft.spage=124&rft.epage=137&rft.pages=124-137&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2019.04.031&rft_dat=%3Celsevier_webof%3ES0272638619308261%3C/elsevier_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31358311&rft_els_id=S0272638619308261&rfr_iscdi=true